MTOR and hyperinsulinemic hypoglycemia: Finally, we tested whether i.ln. MPs avoid safety and tolerability concerns associated with systemic therapies [e.g., mild, transient hepatoxicity and nephrotoxicity observed with mTOR inhibitors, attributable to high trough drug levels (32) or hyperinsulinemic hypoglycemia (33, 34)].